Get the Stockscreener App
2.32
3.57%
0.08
After Hours:
2.36
0.04
+1.72%
Aldeyra Therapeutics Inc stock is traded at $2.32, with a volume of 1.12M.
It is up +3.57% in the last 24 hours and down -64.74% over the past month.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
See More
Previous Close:
$2.24
Open:
$2.26
24h Volume:
1.12M
Relative Volume:
0.80
Market Cap:
$131.36M
Revenue:
-
Net Income/Loss:
$-44.80M
P/E Ratio:
-3.0933
EPS:
-0.75
Net Cash Flow:
$-30.67M
1W Performance:
+5.45%
1M Performance:
-64.74%
6M Performance:
-60.68%
1Y Performance:
-40.97%
1-Day Range:
$2.25
$2.40
1-Week Range:
$1.99
$2.40
52-Week Range:
$1.14
$7.20
Aldeyra Therapeutics Inc Stock (ALDX) Company Profile
Name
Aldeyra Therapeutics Inc
Sector
Industry
Phone
781-761-4904
Address
131 HARTWELL AVENUE, LEXINGTON, MA
Compare ALDX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALDX
Aldeyra Therapeutics Inc
|
2.32 | 131.36M | 0 | -44.80M | -30.67M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
490.47 | 128.67B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
585.49 | 60.99B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
599.87 | 36.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
236.75 | 29.89B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
252.77 | 25.74B | 3.81B | -644.79M | -669.77M | -6.24 |
Aldeyra Therapeutics Inc Stock (ALDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-03-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Apr-02-24 | Resumed | H.C. Wainwright | Buy |
| Apr-27-22 | Resumed | H.C. Wainwright | Buy |
| Feb-08-21 | Initiated | H.C. Wainwright | Buy |
| Dec-16-20 | Initiated | Berenberg | Buy |
| Oct-30-20 | Initiated | Jefferies | Buy |
| Oct-16-20 | Initiated | BTIG Research | Buy |
| Sep-22-20 | Initiated | Alliance Global Partners | Buy |
| May-12-20 | Initiated | Oppenheimer | Outperform |
| Dec-04-18 | Initiated | Citigroup | Buy |
| Sep-26-18 | Reiterated | Cantor Fitzgerald | Overweight |
| Sep-13-18 | Initiated | Janney | Buy |
| Jan-26-18 | Initiated | Seaport Global Securities | Buy |
| Sep-26-16 | Initiated | H.C. Wainwright | Buy |
| Jul-01-16 | Initiated | Stifel | Buy |
| Jul-01-15 | Initiated | Canaccord Genuity | Buy |
| Mar-25-15 | Initiated | Chardan Capital Markets | Buy |
| Mar-20-15 | Reiterated | H.C. Wainwright | Buy |
| Nov-18-14 | Initiated | H.C. Wainwright | Buy |
| Jun-19-14 | Initiated | Aegis Capital | Buy |
View All
Aldeyra Therapeutics Inc Stock (ALDX) Latest News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc.ALDX - PR Newswire
Aldeyra Therapeutics Inc (ALDX) is an excellent investment, but the stock is overvalued/undervalued right now - uspostnews.com
Bragar Eagel & Squire, P.C. Is Investigating TechTarget and Aldeyra and Encourages ... - Bluefield Daily Telegraph
Bragar Eagel & Squire, P.C. Is Investigating TechTarget and Aldeyra and Encourages Investors to Contact the Firm - GlobeNewswire
ALDX Investors Have Opportunity to Join Aldeyra Therapeutics, Inc. Fraud Investigation with the Schall Law Firm - Business Wire
Latest Insider moments: PERCEPTIVE ADVISORS LLC, Aldeyra Therapeutics Inc [ALDX] 10% Owner sold 3,400,000 shares – Knox Daily - knoxdaily.com
Aldeyra Therapeutics, Inc. (ALDX) Faces Scrutiny After - GlobeNewswire
Aldeyra Therapeutics: A Mispriced Gem With Reproxalap's CRL Creating A Golden Buying Opportunity - Seeking Alpha
ALDX LEGAL REMINDER: Did Aldeyra Therapeutics, Inc. Commit - GlobeNewswire
ALDX INVESTOR NEWS: Aldeyra Therapeutics, Inc. Investors - GlobeNewswire
ALDX INVESTOR NEWS: Aldeyra Therapeutics, Inc. Investors may be able to Recover Losses in Class Action Investigation -- Contact BFA Law (NASDAQ:ALDX) - GlobeNewswire Inc.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aldeyra Therapeutics, Inc. (ALDX) and Encourages Shareholders to Learn More About the Investigation - markets.businessinsider.com
Aldeyra Therapeutics, Inc. (ALDX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - markets.businessinsider.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra - Bluefield Daily Telegraph
ALDX INVESTOR INVESTIGATION: Aldeyra Therapeutics, Inc. - GlobeNewswire
Aldeyra Therapeutics Appoints Chip Clark to Board of Directors - citybiz
Aldeyra Therapeutics Appoints Chip Clark to Board of Directors | ALDX Stock News - GuruFocus
30-Year Biotech Leader Chip Clark Strengthens Aldeyra Board: Strategic Move for Pipeline Advancement - Stock Titan
Research Analysts Set Expectations for ALDX Q1 Earnings - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
What is Leerink Partnrs’ Estimate for ALDX Q2 Earnings? - Defense World
Bronstein, Gewirtz & Grossman, LLC Is Investigating Aldeyra Therapeutics, Inc. (ALDX) And Encourages Shareholders to Connect - markets.businessinsider.com
American Century Companies Inc. Reduces Stock Holdings in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - Defense World
Aldeyra (ALDX) Pre-Earnings Options Activity Signals Potential P - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Encourages Aldeyra Therapeutics, Inc. (ALDX) Stockholders to Inquire about Securities Investigation - markets.businessinsider.com
ALDX STOCK REMINDER: The Aldeyra Therapeutics, Inc. - GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aldeyra Therapeutics, Inc. (ALDX) and Encourages Investors to Learn More About the Investigation - markets.businessinsider.com
Aldeyra Therapeutics (NASDAQ:ALDX) Price Target Cut to $9.00 by Analysts at BTIG Research - MarketBeat
ALDX STOCK NOTIFICATION: Did Aldeyra Therapeutics, Inc. - GlobeNewswire
Aldeyra Therapeutics, Inc. (ALDX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - markets.businessinsider.com
Hay Fever Conjunctivitis Therapeutics Market Size in 7MM - openPR.com
Aldeyra Therapeutics, Inc. (ALDX) Faces Scrutiny After Stock Drops 70% On FDA's Reproxalap Complete Response LetterHagens Berman - The Malaysian Reserve
ALDEYRA ALERT: Bragar Eagel & Squire, P.C. is Investigating Aldeyra Therapeutics, Inc. on - Bluefield Daily Telegraph
ALDEYRA ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Aldeyra Therapeutics, Inc. (ALDX) And Encourages Investors to Connect - markets.businessinsider.com
ALDX CLASS NOTICE: An Investigation has been Initiated on - GlobeNewswire
Aldeyra Therapeutics, Inc. (ALDX) Faces Scrutiny After Stock Drops 70% On FDA’s Reproxalap Complete Response Letter – Hagens Berman - TradingView
Aldeyra Therapeutics, Inc. (ALDX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - markets.businessinsider.com
ALDX SECURITIES NOTIFICATION: Aldeyra Therapeutics, Inc. Investors that Suffered Losses are Notified to Contact BFA Law - Newsfile
Aldeyra therapeutics sees $4.83 million stock sale by major shareholder - Investing.com South Africa
After A CRL Setback, Aldeyra Therapeutics Is A Compelling Speculative Buy (NASDAQ:ALDX) - Seeking Alpha
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aldeyra Therapeutics, Inc. (ALDX) and Encourages Stockholders to Learn More About the Investigation - markets.businessinsider.com
Aldeyra’s Dry Eye Drug Gets Another Rejection from the FDA - Contract Pharma
ALDX SECURITIES REPORT: Aldeyra Therapeutics, Inc. - GlobeNewswire
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX): When Will It Breakeven? - simplywall.st
SHAREHOLDER ALERT: Potential Recovery for Aldeyra Therapeutics, Inc. (ALDX) Investors Affected by Stock DropLevi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Aldeyra Therapeutics, Inc. (ALDX) Investors to Inquire about Securities Investigation - markets.businessinsider.com
ALDX SECURITIES NOTICE: Aldeyra Therapeutics, Inc. Investors with Losses are Notified to Contact BFA Law as they may have been Affected by Securities Violations - Newsfile
ALDX SECURITIES ALERT: Aldeyra Therapeutics, Inc. Investors - GlobeNewswire
Aldeyra Therapeutics’ (ALDX) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
INVESTOR ALERT: Investigation of Aldeyra Therapeutics, Inc. (ALDX) Announced by Holzer & Holzer, LLC - GlobeNewswire
Aldeyra Therapeutics Inc Stock (ALDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):